PE20091852A1 - Formulacion farmaceutica que comprende un anticuerpo de ox40l - Google Patents
Formulacion farmaceutica que comprende un anticuerpo de ox40lInfo
- Publication number
- PE20091852A1 PE20091852A1 PE2009000693A PE2009000693A PE20091852A1 PE 20091852 A1 PE20091852 A1 PE 20091852A1 PE 2009000693 A PE2009000693 A PE 2009000693A PE 2009000693 A PE2009000693 A PE 2009000693A PE 20091852 A1 PE20091852 A1 PE 20091852A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical formulation
- formulation including
- ox40l
- agent
- ox40l antibody
- Prior art date
Links
- 102000004473 OX40 Ligand Human genes 0.000 title abstract 3
- 108010042215 OX40 Ligand Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
REFERIDA A UNA FORMULACION FARMACEUTICA QUE COMPRENDE: a) DE 1 MG/ML A 200 MG/ML DE UN ANTICUERPO QUE SE UNE A OX40L Y CONTIENEN UNA PARTE Fc DE ORIGEN HUMANO TAL COMO huMAb OX40L, b) DE 1 mM A 100 Mm DE UN TAMPON TAL COMO TAMPON CITRATO O L-HISTIDINA HCl, c) DE 0,001% A 1% DE UN SURFACTANTE TAL COMO POLISORBATO 20, d) DE 10 mM A 500 mM DE UN AGENTE ESTABILIZADOR O DE 10 mM A 500 mM DE UN AGENTE ESTABILIZADOR Y DE 5 mM A 500 mM DE UN AGENTE DE TONICIDAD O DE 5 mM A 500 mM DE UN AGENTE DE TONICIDAD A UN pH DE ENTRE 4,0 Y 7,0. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO ASMA, ARTRITIS REUMATOIDE, ALERGIA, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156579 | 2008-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091852A1 true PE20091852A1 (es) | 2009-12-31 |
Family
ID=40898050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000693A PE20091852A1 (es) | 2008-05-20 | 2009-05-18 | Formulacion farmaceutica que comprende un anticuerpo de ox40l |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100098712A1 (es) |
| AR (1) | AR071852A1 (es) |
| PE (1) | PE20091852A1 (es) |
| TW (1) | TW201000128A (es) |
| WO (1) | WO2009141239A1 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| EP2399604A1 (en) | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| SMT201700515T1 (it) | 2011-05-02 | 2018-01-11 | Millennium Pharm Inc | Formulazione per anticorpo anti- 4 7 |
| PE20141568A1 (es) | 2011-10-28 | 2014-11-21 | Neotope Biosciences Ltd | Anticuerpos humanizados que reconocen la alfa-sinucleina |
| KR102086061B1 (ko) | 2012-01-27 | 2020-03-11 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US9434785B1 (en) | 2015-04-30 | 2016-09-06 | Kymab Limited | Anti-human OX40L antibodies and methods of treating graft versus host disease with the same |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| CN108064169B (zh) * | 2015-03-03 | 2022-02-11 | 科马布有限公司 | 抗体、用途和方法 |
| BR112017023849A2 (pt) | 2015-05-07 | 2018-07-17 | Agenus Inc. | anticorpos anti-ox40 e métodos de uso dos mesmos |
| MX2018006477A (es) | 2015-12-02 | 2018-09-03 | Agenus Inc | Anticuerpos y metodos de uso de estos. |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
| KR102604433B1 (ko) | 2016-08-09 | 2023-11-24 | 키맵 리미티드 | 항-icos 항체 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| BR112020020741A2 (pt) * | 2018-04-10 | 2021-01-19 | Dr. Reddy's Laboratories Limited | Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. |
| WO2020016417A1 (en) * | 2018-07-19 | 2020-01-23 | Ichnos Sciences S.A. | Liquid antibody formulation |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| EP3999537A1 (en) * | 2019-07-19 | 2022-05-25 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CA3201564A1 (en) | 2020-12-09 | 2022-06-16 | Jung Min Yoo | Anti-ox40l antibody, anti-ox40l/anti-tnfalpha bispecific antibody, and uses thereof |
| TW202506179A (zh) * | 2023-04-14 | 2025-02-16 | 英商凱麥博有限公司 | 含有抗ox40l抗體之醫藥配製物 |
| WO2024227174A2 (en) * | 2023-04-28 | 2024-10-31 | Paragon Therapeutics, Inc. | Antibodies that bind ox40l and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7291331B1 (en) * | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP2009519718A (ja) * | 2005-12-16 | 2009-05-21 | ジェネンテック・インコーポレーテッド | 抗ｏｘ４０ｌ抗体とその使用方法 |
-
2009
- 2009-05-11 WO PCT/EP2009/055647 patent/WO2009141239A1/en not_active Ceased
- 2009-05-18 PE PE2009000693A patent/PE20091852A1/es not_active Application Discontinuation
- 2009-05-19 TW TW098116588A patent/TW201000128A/zh unknown
- 2009-05-20 AR ARP090101807A patent/AR071852A1/es unknown
- 2009-05-20 US US12/454,598 patent/US20100098712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201000128A (en) | 2010-01-01 |
| AR071852A1 (es) | 2010-07-21 |
| WO2009141239A1 (en) | 2009-11-26 |
| US20100098712A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| MY166045A (en) | Abeta antibody formulation | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| PE20081477A1 (es) | Formulacion liofilizada mab abeta | |
| EA031209B9 (ru) | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения | |
| AR067011A1 (es) | Formulaciones de anticuerpos | |
| CL2007003193A1 (es) | Metodo para evitar o reducir la vasoconstriccion a continuacion de la administracion de un portador de oxigeno vasoactivo, que comprende oxido nitrico gaseoso y otro agente activo; composicion farmaceutica que comprende un inhibidor de fosfodiesteras | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| PE20091328A1 (es) | Formulacion de anticuerpo | |
| PE20121396A1 (es) | Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| PE20142314A1 (es) | Composiciones intranasales de dexmedetomidina y metodos de uso de ellas | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| JP2010529999A5 (es) | ||
| EA201070121A1 (ru) | Лекарственная форма, содержащая слитый белок glp-1-fc | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| MX2019006881A (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
| PE20081751A1 (es) | Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor | |
| MX383583B (es) | Composiciones organicas para tratar enfermedades relacionadas con beta-enac. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |